Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 28;228(1):4-7.
doi: 10.1093/infdis/jiad010.

Respiratory Syncytial Virus Infection: Old Challenges and New Approaches

Octavio Ramilo  1 , Rosa Rodriguez-Fernandez  2   3 , Asuncion Mejias  4   5
Affiliations

Respiratory Syncytial Virus Infection: Old Challenges and New Approaches

Octavio Ramilo et al. J Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. OR has received research grants to institution from Janssen, Merck, NIH, and the Bill & Melinda Gates foundation; and fees for participation in Advisory Boards from Sanofi-Pasteur, Merck, Lilly, Adagios, and Pfizer and for lectures from Pfizer, Sanofi-Pasteur, and Astra-Zeneca. AM has received fees for participation in Advisory Boards from Janssen, Merck, and Sanofi-Pasteur, grants to institution from Merck and Janssen, and fees for lectures from Sanofi-Pasteur and Astra-Zeneca. RR-F has received fees for lectures from Abbvie, Astra Zeneca, and Sanofi; fees for participation in Advisory Boards from Sanofi, Astra Zeneca and Merck; and research grants from FIS (Fondo de Investigaciones Sanitarias). Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Respiratory syncytial virus (RSV) vaccine platforms and monoclonal antibodies. The prefusion (preF) RSV form of the protein F has been successfully included in different vaccine constructs, including an adenovirus 26 (Ad26) vaccine expressing preF combined with preF protein vaccine (Janssen) (1A), an adjuvanted RSV preF3 (Glaxo) (1B), and a bivalent RSV A and B preF vaccine (Pfizer) (1C). In addition, newer generation monoclonal antibodies with extended half-life due to modifications in the Fc region (YTE technology) are also undergoing clinical trials targeting either site O present only in the prefusion form of the F protein (nirsevimab [1D]) or site IV, which is present in both the preF and postfusion (postF) conformations (clesrovimab [1E]).
See this image and copyright information in PMC

References

    1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–98. - PMC - PubMed
    1. Wildenbeest JG, Billard MN, Zuurbier RP, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med 2022:S2213–2600(22)00414–3. doi:10.1016/S2213-2600(22)00414-3. Online ahead of print. - DOI - PMC - PubMed
    1. Garcia CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126:e1453–60. - PMC - PubMed
    1. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis 2022; 9:ofac300. - PMC - PubMed
    1. Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017–2020. Clin Infect Dis 2022; 74:1004–11. - PubMed

Publication types